UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000001995
Receipt No. R000002432
Scientific Title Randomized Parallel Group Phase II Clinical Study of Sorafenib/Interferon Combination Therapy and Sunitinib Monotherapy for Advanced Renal Cell Carcinoma
Date of disclosure of the study information 2009/05/21
Last modified on 2018/11/01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Randomized Parallel Group Phase II Clinical Study of Sorafenib/Interferon Combination Therapy and Sunitinib Monotherapy for Advanced Renal Cell Carcinoma
Acronym Comparative Study of Sorafenib/IFN Combination Therapy and Sunitinib Monotherapy for Advanced RCC
Scientific Title Randomized Parallel Group Phase II Clinical Study of Sorafenib/Interferon Combination Therapy and Sunitinib Monotherapy for Advanced Renal Cell Carcinoma
Scientific Title:Acronym Comparative Study of Sorafenib/IFN Combination Therapy and Sunitinib Monotherapy for Advanced RCC
Region
Japan

Condition
Condition Advanced renal cell carcinoma
Classification by specialty
Urology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The efficacy and safety of sorafenib/IFN combination therapy and sunitinib monotherapy for progressive renal cell carcinoma are comparatively studied in patients without history of systemic therapy for progressive renal cell carcinoma.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Progression-free survival
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Four-week subcutaneous administration of Sumiferon 6 million units three times a week is followed by oral administration of sorafenib 400 mg bid. The combination therapy with Sumiferon and sorafenib is continued until the disease status is assessed as PD.
Interventions/Control_2 Four-week oral administration of sunitinib 50 mg qd is followed by 2-week drug withdrawal: this 6-week course is repeated until the disease status is PD.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Patients diagnosed as having renal cell carcinoma with histopathological clear cell carcinoma components
2.Patients with extrapulmonary metastasis or poor-risk patients in MSKCC risk category
3.Patients with measurable lesions according to the RECIST
4.Patients in whom drug therapy, radiotherapy, or surgical therapy lowered the acute toxicity to Grade 1 or below according to the CTCAE ver. 3.0
5.Patients aged 20 years or older
6.Patients in whom performance status in ECOG (Eastern Cooperative Oncology Group) classification is 0 to 1
7.Patients who are expected to survive for at least 3 months
8.Patients in whom the function of primary organs are retained
9.Female patients who are postmenopausal have consented to contraception or has been surgically sterilized. Male patients who have consented to contraception or received sterilization
10.Patients from whom the informed consent is obtained in writing
Key exclusion criteria 1.Patients who have received systemic therapy for renal carcinoma
2.Patients who completed the surgery or radiotherapy for renal carcinoma less than 4 weeks before initiation of the present study
3.Patients suffering from multiple cancers within last 5 years, excepting those who received appropriate treatment for the following
a. Basal cell carcinoma or squamous cell carcinoma of skin
b. Uterine cervix carcinoma, gastric cancer or large intestine carcinoma (in situ)
4. Patients who are diagnosed as having cerebral metastasis, meningeal metastasis, spinal cord compression, or meningitis carcinomatosa
5. Patients who are found to have either of the following diseases within 12 months before initiation of the present study
Myocardial infarction, severe or unstable angina, coronary or peripheral arterial bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
6. Patients with arrhythmia (Grade 2 or severer according to the CTCAE ver. 3.0) or atrial fibrillation (regardless of Gragde), or male patients with QTc interval prolonged over 450 msec or female patients with QTc interval prolonged over 470 msec
Target sample size 200

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hirotsugu Uemura
Organization Kinki University School of Medicine
Division name Department of Urology
Zip code
Address 377-2 Ohno-higashi, Osaka-Sayama, Osaka, Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name Masahiro Nozawa
Organization Osaka Urological Oncology Research Group
Division name Executive Office
Zip code
Address 377-2 Ohno-higashi, Osaka-Sayama, Osaka, Japan
TEL
Homepage URL
Email

Sponsor
Institute Osaka Urological Oncology Research Group
Institute
Department

Funding Source
Organization Osaka Kidney Foundation
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2009 Year 05 Month 21 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2009 Year 01 Month 30 Day
Date of IRB
Anticipated trial start date
2009 Year 08 Month 01 Day
Last follow-up date
2012 Year 08 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2009 Year 05 Month 21 Day
Last modified on
2018 Year 11 Month 01 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002432

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.